Skip to content

NMN for Age-Related Macular Degeneration: What the Evidence Actually Shows

Category: neurological | ICD-10: H35.30 | Evidence tier: mechanistic-only

What is Age-Related Macular Degeneration?

Age-related macular degeneration is the leading cause of central vision loss in older adults. It exists in dry (atrophic) and wet (neovascular) forms with different treatments.

NMN relevance: the published evidence

AREDS2 vitamin formulations and anti-VEGF injections have human evidence in AMD. NMN has no completed AMD trial. Mechanistic interest exists around retinal NAD+ and mitochondrial health, but clinical translation is unproven.

Questions to ask before supplementing

No dose validated in AMD.

Contraindications and red flags

Do not delay AREDS2 supplementation or anti-VEGF therapy when prescribed.

Bottom line for Malaysian patients

NMN is not registered with NPRA as a treatment for any specific condition; it is sold as a general health supplement. If you have age-related macular degeneration, use this page as a question list for a registered medical practitioner before adding NMN to existing therapy. Read our safety guide for full red-flag context.

Related conditions

Cited references